JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

Search

Eli Lilly and Co.

Fechado

SetorSaúde

724.73 1.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

722.59

Máximo

727.03

Indicadores-chave

By Trading Economics

Rendimento

2.9B

5.7B

Vendas

2.8B

16B

P/E

Médio do Setor

49.247

35.69

EPS

6.31

Rendimento de Dividendos

0.74

Margem de lucro

36.384

Funcionários

47,000

EBITDA

3.3B

7.5B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+24.35% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.74%

3.08%

Próximos Ganhos

30 de out. de 2025

Próxima data de dividendos

9 de dez. de 2025

Próxima data de ex-dividendo

14 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-14B

677B

Abertura anterior

723.21

Fecho anterior

724.73

Sentimento de Notícias

By Acuity

26%

74%

52 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Eli Lilly and Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de set. de 2025, 03:10 UTC

Aquisições, Fusões, Aquisições de Empresas

South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility

25 de ago. de 2025, 15:59 UTC

Grandes Movimentos do Mercado

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7 de ago. de 2025, 11:36 UTC

Ganhos

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

26 de set. de 2025, 13:55 UTC

Ganhos

These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More -- Barrons.com

26 de set. de 2025, 09:41 UTC

Ganhos

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More -- Barrons.com

23 de set. de 2025, 02:55 UTC

Aquisições, Fusões, Aquisições de Empresas

South Korea's Celltrion Plans to Invest $1B to Acquire, Expand U.S. Facility

23 de set. de 2025, 01:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Celltrion: Investment Aims to Remove U.S. Tariff Risks

23 de set. de 2025, 01:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Celltrion: To Invest Extra KRW700B to Expand Facility in Branchburg, New Jersey

23 de set. de 2025, 01:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Celltrion: To Spend KRW700B for Acquisition, Initial Operating Costs

23 de set. de 2025, 01:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Celltrion to Buy Biologics Facility in U.S. for $330M From Eli Lilly

22 de set. de 2025, 13:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

26 de ago. de 2025, 13:57 UTC

Ganhos

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26 de ago. de 2025, 11:37 UTC

Ganhos

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12 de ago. de 2025, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 de ago. de 2025, 19:34 UTC

Conversa de Mercado

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 de ago. de 2025, 05:32 UTC

Conversa de Mercado

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 de ago. de 2025, 16:20 UTC

Ganhos

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 de ago. de 2025, 14:18 UTC

Conversa de Mercado
Ganhos

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 de ago. de 2025, 13:54 UTC

Ganhos

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 de ago. de 2025, 12:12 UTC

Ganhos

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 de ago. de 2025, 11:58 UTC

Ganhos

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7 de ago. de 2025, 11:32 UTC

Ganhos

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 11:03 UTC

Ganhos

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 10:49 UTC

Ganhos

Eli Lilly 2Q Gross Margin 84.3% >LLY

7 de ago. de 2025, 10:48 UTC

Ganhos

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7 de ago. de 2025, 10:47 UTC

Ganhos

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7 de ago. de 2025, 10:46 UTC

Ganhos

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7 de ago. de 2025, 10:46 UTC

Ganhos

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7 de ago. de 2025, 10:46 UTC

Ganhos

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7 de ago. de 2025, 10:45 UTC

Ganhos

Eli Lilly 2Q Net $5.66B >LLY

Comparação entre Pares

Variação de preço

Eli Lilly and Co. Previsão

Preço-alvo

By TipRanks

24.35% parte superior

Previsão para 12 meses

Média 900.94 USD  24.35%

Máximo 1,190 USD

Mínimo 700 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Eli Lilly and Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

18

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 884.54Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

52 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat